Oral Therapy for Erectile Dysfunction

[1]  S. Hayreh.  Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[2]  W. Shen,et al.  The efficacy of tadalafil in clinical populations. , 2005, The journal of sexual medicine.

[3]  M. Thibonnier,et al.  Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. , 2005, The Journal of urology.

[4]  David M Pinkstaff,et al.  871: Can Patients Failing a PDE 5-Inhibitor be Rescued by Another Tablet?: An Objective Assessment of 331 Patients with Erectile Dysfunction , 2005 .

[5]  A. Bhavsar,et al.  Nonarteritic Ischemic Optic Neuropathy Developing Soon After Use of Sildenafil (Viagra): A Report of Seven New Cases , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[6]  E. Bischoff.  Pharmacology of Phosphodiesterase Inhibitors , 2005 .

[7]  H. Padma-nathan.  Sildenafil Citrate, the Classic PDE5 Inhibitor , 2005 .

[8]  A. Nehra.  Vardenafil Clinical Trials Experience , 2005 .

[9]  T. H. Klotz,et al.  Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? , 2005, International Journal of Impotence Research.

[10]  D. Wheatley.  Triple‐blind, placebo‐controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs , 2004, Human psychopharmacology.

[11]  J. Crook,et al.  Success of sildenafil for erectile dysfunction in men treated with brachytherapy or external beam radiation for prostate cancer. , 2004, The Canadian journal of urology.

[12]  J. Mulhall.  Understanding erectile dysfunction medication preference studies , 2004, Current opinion in urology.

[13]  F. Montorsi,et al.  Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. , 2004, The journal of sexual medicine.

[14]  L. Derogatis,et al.  Revised definitions of women's sexual dysfunction. , 2004, The journal of sexual medicine.

[15]  M. Hareyama,et al.  Erectile function following external beam radiotherapy for clinically organ-confined or locally advanced prostate cancer. , 2004, Japanese journal of clinical oncology.

[16]  I. Goldstein,et al.  Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. , 2004, The Urologic clinics of North America.

[17]  T. Costigan,et al.  A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. , 2004, European urology.

[18]  I. Abdel-Hamid.  Phosphodiesterase 5 Inhibitors in Rapid Ejaculation , 2004, Drugs.

[19]  E. Klein,et al.  Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. , 2003, Urology.

[20]  J. Denne,et al.  A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. , 2003, Clinical therapeutics.

[21]  M. Gleave,et al.  Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. , 2003, The Journal of urology.

[22]  D. Kuban,et al.  Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. , 2003, Urology.

[23]  J. Mulhall,et al.  Novel agents for sexual dysfunction , 2003, BJU international.

[24]  W. Hellstrom,et al.  Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. , 2003, The Journal of urology.

[25]  J. Orazem,et al.  Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. , 2003, Urology.

[26]  R. Rosen,et al.  Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. , 2003, Urology.

[27]  F. Montorsi,et al.  Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time , 2003, International Journal of Impotence Research.

[28]  P. Rajagopalan,et al.  Effect of High‐Fat Breakfast and Moderate‐Fat Evening Meal on the Pharmacokinetics of Vardenafil, an Oral Phosphodiesterase‐5 Inhibitor for the Treatment of Erectile Dysfunction , 2003, Journal of clinical pharmacology.

[29]  F. Montorsi,et al.  Long-term safety experience with tadalafil , 2003 .

[30]  R. Stanislavov,et al.  Treatment of Erectile Dysfunction with Pycnogenol and L-arginine , 2003, Journal of sex & marital therapy.

[31]  E. Bischoff,et al.  Phosphodiesterase type 5 (PDE5) inhibitors. , 2003, Progress in medicinal chemistry.

[32]  N. Mabjeesh,et al.  Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. , 2003, Urology.

[33]  F. Montorsi,et al.  A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. , 2002, The Journal of urology.

[34]  W. Hellstrom,et al.  Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. , 2002, Journal of andrology.

[35]  T. Costigan,et al.  Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. , 2002, The Journal of urology.

[36]  E. Zrenner,et al.  Viagra® (sildenafil citrate) and ophthalmology , 2002, Progress in Retinal and Eye Research.

[37]  D. Hatzichristou,et al.  Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. , 2002, Urology.

[38]  A. Burnett,et al.  The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. , 2002, Urology.

[39]  F. Montorsi,et al.  A 4-year update on the safety of sildenafil citrate (Viagra). , 2002, Urology.

[40]  J. Corbin,et al.  PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS , 2002, International journal of clinical practice.

[41]  G. Muirhead,et al.  Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. , 2002, British journal of clinical pharmacology.

[42]  G. Muirhead,et al.  The effects of sildenafil on human sperm function in healthy volunteers. , 2002, British journal of clinical pharmacology.

[43]  S. Phillips,et al.  Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families , 2002 .

[44]  P. Cuevas,et al.  The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil , 2001, International Journal of Impotence Research.

[45]  A. McCullough,et al.  Prevention and management of erectile dysfunction following radical prostatectomy. , 2001, The Urologic clinics of North America.

[46]  I. Goldstein,et al.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial , 2001, International Journal of Impotence Research.

[47]  G. Hackett,et al.  THREE‐YEAR UPDATE OF SILDENAFIL CITRATE (VIAGRA®) EFFICACY AND SAFETY , 2001, International journal of clinical practice.

[48]  H. Herrmann,et al.  Hemodynamic effects of sildenafil in men with severe coronary artery disease. , 2000, The New England journal of medicine.

[49]  A. Isidori,et al.  Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. , 2000, Human reproduction.

[50]  H. Lepor,et al.  SSI Prize Essay for Male Erectile Dysfunction—Clinical ‘Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP)’ , 1999, International Journal of Impotence Research.

[51]  J. Corbin,et al.  Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. , 1999, Molecular pharmacology.

[52]  I. Sharlip.  Evaluation and nonsurgical management of erectile dysfunction. , 1998, The Urologic clinics of North America.

[53]  L. Ignarro,et al.  Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission , 1992 .

[54]  J. Owen,et al.  DOUBLE-BLIND TRIAL OF YOHIMBINE IN TREATMENT OF PSYCHOGENIC IMPOTENCE , 1987, The Lancet.